Opus Genetics
IRD
43 hedge funds and large institutions have $16.5M invested in Opus Genetics in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 9 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
12% more capital invested
Capital invested by funds: $14.7M → $16.5M (+$1.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.55% less ownership
Funds ownership: 32.89% → 29.34% (-3.6%)
7% less funds holding
Funds holding: 46 → 43 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
+$2.49M |
| 2 |
VC
Voss Capital
Houston,
Texas
|
+$362K |
| 3 |
MBAM
Mink Brook Asset Management
West Palm Beach,
Florida
|
+$359K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$174K |
| 5 |
Millennium Management
New York
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$515K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$164K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$69K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$62.9K |
| 5 |
BlackRock
New York
|
-$57.8K |
IRD Hedge Fund Activity: Q2 2025 in Review
43 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2025, worth a combined $16.5M — up 12% from $14.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IRD and 7 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 10 added.
The largest buyer was BIOS Capital Management, adding an estimated $2.49M. The largest seller was AWM Investment Company, exiting entirely with an estimated $515K sold.
- 43 institutional investors held Opus Genetics (IRD) as of Q2 2025, down from 46 in Q1 2025.
- Funds reported $16.5M of Opus Genetics stock for Q2 2025, up 12% quarter-over-quarter.
- 7 funds opened new Opus Genetics positions in Q2 2025 and 9 closed out, a net change of -2 holders.
- The largest Opus Genetics buyer in Q2 2025 was BIOS Capital Management, an estimated $2.49M added.
- The largest Opus Genetics seller in Q2 2025 was AWM Investment Company, an estimated $515K sold.
Based on aggregated 13F filings for Q2 2025.